维普期刊资源整合服务平台（V6.5）

328篇 您的检索式：作者名="Feagan"

选中清除导出查看参考文献查看引证文献引用追踪共17页首页上一页第1页下一页末页 /17 跳转

	题名	作者	年代	出处	被引量
1	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘	William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Toshifumi Hibi Paul Rutgeerts	2013	Gastroenterology2013，，：	6
2	Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial显示文摘	Stephen B Hanauer Brian G Feagan Gary R Lichtenstein Lloyd F Mayer S Schreiber Jean Frederic Colombel Daniel Rachmilewitz Douglas C Wolf Allan Olson Weihang Bao Paul Rutgeerts	2002	The Lancet2002，，9317：	6
3	Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘	William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Paul Rutgeerts	2013	Gastroenterology2013，，：	5
4	International Consensus Statement on surveillance and management of dysplasia in inflammatory bowel disease显示文摘	Loren Laine Tonya Kaltenbach Alan Barkun Kenneth R. McQuaid Venkataraman Subramanian Roy Soetikno James E. East Francis A. Farraye Brian Feagan John Ioannidis Ralf Kiesslich Michael Krier Takayuki Matsumoto Robert P. McCabe Klaus M?nkemüller Robert Odze M	2014	Gastrointestinal Endoscopy2014，，：	3
5	Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis显示文摘	Jean Frédéric Colombel Paul Rutgeerts Walter Reinisch Dirk Esser Yanxin Wang Yinghua Lang Colleen W. Marano Richard Strauss Bj?rn J. Oddens Brian G. Feagan Stephen B. Hanauer Gary R. Lichtenstein Daniel Present Bruce E. Sands William J. Sandborn	2011	Gastroenterology2011，，4：	3
6	<ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘	Geert D’Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland	2007	Gastroenterology2007，，2：	2
7	Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry显示文摘	Gary R. Lichtenstein Brian G. Feagan Russell D. Cohen Bruce A. Salzberg Robert H. Diamond Donny M. Chen Michelle L. Pritchard William J. Sandborn	2006	Clinical Gastroenterology and Hepatology2006，，5：	2
8	Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose‐ranging study显示文摘	Asit Parikh Timothy Leach Tim Wyant Catherine Scholz Serap Sankoh Diane R. Mould Terry Ponich Irving Fox Brian G. Feagan	2011	Inflamm Bowel Dis2011，，8：	2
9	Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed显示文摘	Bruce E. Sands Brian G. Feagan Paul Rutgeerts Jean-Frédéric Colombel William J. Sandborn Richmond Sy Geert D’Haens Shomron Ben-Horin Jing Xu Maria Rosario Irving Fox Asit Parikh Catherine Milch Stephen Hanauer	2014	Gastroenterology2014，，：	2
10	Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn’s Disease: Results From the CHARM Study显示文摘	Brian G. Feagan Remo Panaccione William J. Sandborn Geert R. D’Haens Stefan Schreiber Paul J. Rutgeerts Edward V. Loftus Kathleen G. Lomax Andrew P. Yu Eric Q. Wu Jingdong Chao Parvez Mulani	2008	Gastroenterology2008，，5：	2
11	<ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘	Geert D'Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland	2007	Gastroenterology2007，，2：	2
12	Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn’s Disease显示文摘	Jennifer Jones Edward V. Loftus Remo Panaccione Li–Sheng Chen Sandra Peterson Joseph Mcconnell Linnea Baudhuin Karen Hanson Brian G. Feagan Scott W. Harmsen Alan R. Zinsmeister Emelie Helou William J. Sandborn	2008	Clinical Gastroenterology and Hepatology2008，，11：	2
13	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial 显示文摘	Sandborn W J Schreiber S Feagan B G	2011	Clin Gastroenterol Hepatol2011，9，8：	1
14	Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease显示文摘	Ingrid Ordás Brian G. Feagan William J. Sandborn	2012	Clinical Gastroenterology and Hepatology2012，，10：	1
15	Infliximab forinduction and maintenance therapy for ulcerative colitis显示文摘	RUTGEERTS P SANDBORN W J FEAGAN B G	2005	NEngl J Med2005，353，23：	1
16	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial显示文摘	HANAUER SB FEAGAN BG LICHTENSTEIN GR	2002	Lancet2002，359，9317：	1
17	A review of activ ity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis显示文摘	ErHaens G Sandborn WJ Feagan BG	2007	Gastroenterology2007，132，2：	1
18	A review of activi- ty indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis 显示文摘	D'Haens G Sandborn WJ Feagan BG	2007	Gastroenterology2007，132，2：	1
19	Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘	Rutgeerts P Sandborn W J Feagan B G		New England Journal of Medicine0，，：	1
20	Low-Dose Cyclosporine for the Treatment of Crohn's Disease显示文摘	Feagan G John M	1994	Med1994，330，：	1

返回顶部每页显示：

共17页首页上一页第1页下一页末页 /17 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示